Latest News about IMGN
Recent news which mentions IMGN
Ardelyx To Rally 160%? Here Are 10 Other Price Target Changes For Friday
December 30, 2022
From Benzinga
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
December 02, 2022
From Benzinga
Why Jim Cramer Sees 'Another Bad Quarter Ahead' For Ford, And What Will Turn Things Around
November 23, 2022
From Benzinga
After FDA Approval For Ovarian Cancer Drug, ImmunoGen Becomes Top Pick For This Analyst
November 16, 2022
Tickers
IMGN
From Benzinga
Why Fast Radius Shares Plunged Around 48%; Here Are 103 Biggest Movers From Yesterday
November 16, 2022
From Benzinga
Vodafone, Getty Images Holdings, Haynes International And Some Other Big Stocks Moving Lower On Tuesday
November 15, 2022
From Benzinga
PDS Biotechnology To Rally Around 129%? Here Are 5 Other Price Target Changes For Tuesday
November 15, 2022
From Benzinga
HUYA, Tencent Music Entertainment, Taiwan Semiconductor Manufacturing, And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
November 15, 2022
From Benzinga
FDA Grants Conditional Approval To First Antibody Drug Conjugate From ImmunoGen For Pretreated Ovarian Cancer
November 15, 2022
From Benzinga
Earnings Scheduled For November 4, 2022
November 04, 2022
From Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
September 09, 2022
From Benzinga
From Benzinga
From Benzinga
Earnings Scheduled For July 29, 2022
July 29, 2022
From Benzinga
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.